Cara Therapeutics Inc. (CARA) and XBiotech Inc. (NASDAQ:XBIT) Comparison side by side

Cara Therapeutics Inc. (NASDAQ:CARA) and XBiotech Inc. (NASDAQ:XBIT) compete against each other in the Biotechnology sector. We will contrast them and contrast their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Valuation & Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cara Therapeutics Inc. 7.94M 84.25 67.54M -1.18 0.00 XBiotech Inc. N/A 0.00 22.28M -0.65 0.00 Demonstrates Cara Therapeutics Inc. and XBiotech Inc. earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 hightlights the return on assets, return on equity and net margins of the two companies. Net Margins Return on Equity Return on Assets Cara Therapeutics Inc. -850.63% -70.8% -50.9% XBiotech Inc. 0.00% -41.4% -39.5% Volatility & Risk

Cara Therapeutics Inc. has a 2.93 beta, while its volatility is 193.00%, thus making it more volatile than Standard and Poor’s 500. In other hand, XBiotech Inc. has beta of 0.14 which is 86.00% less volatile than Standard and Poor’s 500.

Liquidity

4.9 and 4.9 are the respective Current Ratio and a Quick Ratio of Cara Therapeutics Inc. Its rival XBiotech Inc.’s Current and Quick Ratios are 9.3 and 9.3 respectively. XBiotech Inc. has a better chance of clearing its pay short and long-term debts than Cara Therapeutics Inc.

Analyst Ratings

The following table given below contains the ratings and recommendations for Cara Therapeutics Inc. and XBiotech Inc.

The consensus price target of Cara Therapeutics Inc. is $22.67, with potential upside of 33.75%.

Insider & Institutional Ownership

Roughly 61.2% of Cara Therapeutics Inc. shares are owned by institutional investors while 4.3% of XBiotech Inc. are owned by institutional investors. Cara Therapeutics Inc.’s share owned by insiders are 2.9%. Insiders Comparatively, owned 9.5% of XBiotech Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders. Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD) Cara Therapeutics Inc. -12.93% -19.69% -21.56% -3.12% 21.12% 29.33% XBiotech Inc. -7.59% 4.55% 48.92% -3.04% -7.38% 5.08% For the past year Cara Therapeutics Inc. has stronger performance than XBiotech Inc.

Summary

XBiotech Inc. beats Cara Therapeutics Inc. on 6 of the 10 factors.

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. It is developing product candidates that target the body’s peripheral nervous system. The companyÂ’s lead product candidate comprises I.V. CR845, which is in Phase III clinical trials for the treatment of patients with acute postoperative pain in adult patients, as well as in Phase II/III clinical trial for the treatment of uremic pruritus disease. It is also developing Oral CR845 that is in Phase IIb clinical trial to treat moderate-to-severe acute and chronic pain, as well as in Phase I clinical trial to treat uremic pruritus; and CR701, which is in preclinical trial for the treatment of neuropathic and inflammatory pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845 for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845 in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.

Tags:, ,